Jin-Gu Lee1,2, Weiliang Huang3, Hangnoh Lee1,2, Joyce van de Leemput1,2, Maureen A Kane3, Zhe Han4,5. 1. Center for Precision Disease Modeling, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. 2. Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. 3. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA. 4. Center for Precision Disease Modeling, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. zhan@som.umaryland.edu. 5. Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. zhan@som.umaryland.edu.
Abstract
BACKGROUND: SARS-CoV-2 causes COVID-19 which has a widely diverse disease profile. The mechanisms underlying its pathogenicity remain unclear. We set out to identify the SARS-CoV-2 pathogenic proteins that through host interactions cause the cellular damages underlying COVID-19 symptomatology. METHODS: We examined each of the individual SARS-CoV-2 proteins for their cytotoxicity in HEK 293 T cells and their subcellular localization in COS-7 cells. We also used Mass-Spec Affinity purification to identify the host proteins interacting with SARS-CoV-2 Orf6 protein and tested a drug that could inhibit a specific Orf6 and host protein interaction. RESULTS: We found that Orf6, Nsp6 and Orf7a induced the highest toxicity when over-expressed in human 293 T cells. All three proteins showed membrane localization in COS-7 cells. We focused on Orf6, which was most cytotoxic and localized to the endoplasmic reticulum, autophagosome and lysosomal membranes. Proteomics revealed Orf6 interacts with nucleopore proteins (RAE1, XPO1, RANBP2 and nucleoporins). Treatment with Selinexor, an FDA-approved inhibitor for XPO1, attenuated Orf6-induced cellular toxicity in human 293 T cells. CONCLUSIONS: Our study revealed Orf6 as a highly pathogenic protein from the SARS-CoV-2 genome, identified its key host interacting proteins, and Selinexor as a drug candidate for directly targeting Orf6 host protein interaction that leads to cytotoxicity.
BACKGROUND:n class="Species">SARS-CoV-2 causes COVID-19 which has a widely diverse disease profile. The mechanisms underlying its pathogenicity remain unclear. We set out to identify the SARS-CoV-2 pathogenic proteins that through host interactions cause the cellular damages underlying COVID-19 symptomatology. METHODS: We examined each of the individual SARS-CoV-2 proteins for their cytotoxicity in HEK 293 T cells and their subcellular localization in COS-7 cells. We also used Mass-Spec Affinity purification to identify the host proteins interacting with SARS-CoV-2Orf6 protein and tested a drug that could inhibit a specific Orf6 and host protein interaction. RESULTS: We found that Orf6, Nsp6 and Orf7a induced the highest toxicity when over-expressed in human 293 T cells. All three proteins showed membrane localization in COS-7 cells. We focused on Orf6, which was most cytotoxic and localized to the endoplasmic reticulum, autophagosome and lysosomal membranes. Proteomics revealed Orf6 interacts with nucleopore proteins (RAE1, XPO1, RANBP2 and nucleoporins). Treatment with Selinexor, an FDA-approved inhibitor for XPO1, attenuated Orf6-induced cellular toxicity in human 293 T cells. CONCLUSIONS: Our study revealed Orf6 as a highly pathogenic protein from the SARS-CoV-2 genome, identified its key host interacting proteins, and Selinexor as a drug candidate for directly targeting Orf6 host protein interaction that leads to cytotoxicity.
Authors: Matthew Frieman; Boyd Yount; Mark Heise; Sarah A Kopecky-Bromberg; Peter Palese; Ralph S Baric Journal: J Virol Date: 2007-06-27 Impact factor: 5.103
Authors: Viktoria Dorfer; Peter Pichler; Thomas Stranzl; Johannes Stadlmann; Thomas Taus; Stephan Winkler; Karl Mechtler Journal: J Proteome Res Date: 2014-06-26 Impact factor: 4.466
Authors: Katrina Lythgoe; Sebastian Bonhoeffer; Christophe Fraser; Gabriel E Leventhal; George Shirreff; T Déirdre Hollingsworth; Samuel Alizon Journal: Science Date: 2014-03-21 Impact factor: 47.728
Authors: Lauren Jelley; Jordan Douglas; Xiaoyun Ren; David Winter; Andrea McNeill; Sue Huang; Nigel French; David Welch; James Hadfield; Joep de Ligt; Jemma L Geoghegan Journal: Nat Commun Date: 2022-07-12 Impact factor: 17.694
Authors: Danielle G May; Laura Martin-Sancho; Valesca Anschau; Sophie Liu; Rachel J Chrisopulos; Kelsey L Scott; Charles T Halfmann; Ramon Díaz Peña; Dexter Pratt; Alexandre R Campos; Kyle J Roux Journal: bioRxiv Date: 2021-09-21
Authors: Elizabeth Geerling; Amanda N Pinski; Taylor E Stone; Richard J DiPaolo; Michael Z Zulu; Kevin J Maroney; James D Brien; Ilhem Messaoudi; Amelia K Pinto Journal: iScience Date: 2021-12-03